Motif Bio Plc (LON:MTFB) is the topic of conversation when DirectorsTalk caught up with Dr Gary Waanders the Director of Healthcare Research at Zeus Capital. Gary covers the highlights for
Motif Bio plc (LON:MTFB, NASDAQ:MTFB), is a late clinical stage antibiotic development company. The company completed its IPO on NASDAQ in November last year raising $25m before expenses. With the
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that Robert Dickey IV has been appointed as Chief Financial Officer. Mr.
Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, further to its announcement of 9 August 2016, said today that it is continuing to work
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that it will be presenting two poster studies at IDWeek, October 26
Motif Bio Plc (LON:MTFB), is a late clinical stage antibiotic development company. This morning the company announced that its iclaprim phase III clinical trial in acute bacterial skin and skin
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has given DirectorsTalk an update to REVIVE-1, one of Motif Bio’s two Phase 3 clinical
An article recently published by This is Money singled out a handful of pharmaceutical companies including Motif Bio Plc (LON:MTFB) and Optibiotix Health plc (LON:OPTI) as good small cap ideas.
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that following the conference call for analysts and investors that took place
Zeus Capital’s Dr. Gary Waanders discusses Motif Bio in this exclusive interview with DirectorsTalk
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
